Prometic Life Sciences Inc. (Prometic) closed the acquisition of all the issued and outstanding common shares of Telesta Therapeutics Inc. (Telesta), on October 31, 2016.
“We welcome all of Telesta’s stakeholders’ decision to participate to Prometic’s growth as they will benefit from our ability to further leverage Telesta’s assets”, stated Mr. Pierre Laurin, Prometic’s President and Chief Executive Officer.
Prometic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics. Prometic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Europe, Russia, Asia and Australia.